Colgate-Palmolive’s global oral-care moat and dependable cash returns support a defensive long-term holding, but North American volume weakness and a roughly 24x forward P/E limit near-term upside.
Overview
Colgate-Palmolive is a global consumer-staples company selling Oral Care, Personal Care, Home Care, and Pet Nutrition in more than 200 countries. FY2025 net sales were $20.38 billion and operating cash flow was $4.2 billion; Oral, Personal, and Home Care account for 77% of sales and Hill’s Pet Nutrition for 23%. Its competitive position rests on leading global toothpaste and manual-toothbrush shares of 41.2% and 32.4%, respectively, plus Hill’s veterinarian-led therapeutic niche and broad distribution. Q2 2026 sales increased 4.9% to $5.361 billion, while organic sales grew 2.4%; base-business EPS of $0.99 exceeded $0.95 consensus. Non-GAAP gross margin expanded 100 basis points to 60.1%, but operating margin contracted to 19.0% from 21.1%, and North American sales fell 3.0%. Management reaffirmed 2026 organic-sales growth guidance of 1%–4% and low-to-mid-single-digit non-GAAP EPS growth. At $93.82, shares trade at 24.2x forward EPS of $3.87, with a 2.4% dividend yield. **The franchise is defensive and cash-generative, but expected returns are modest at this valuation.** Near-term catalysts are margin delivery from pricing and productivity, recovery in North American volumes, and Q3 results scheduled for October 30, 2026.